Clinical Trials Logo

Clinical Trial Summary

Radiation therapy (RT) is used in at least 50% of cancer patients and is critical in treating and palliating tumor-related symptoms. Normal tissue radiation toxicity remains an overwhelming obstacle in treating cancer patients with localized tumors. Mucositis is the inflammation and ulceration of the oral and gastrointestinal mucosa observed with different cancer therapies. Oral mucositis is a common, severe, and debilitating complication of RT occurring several days to weeks after RT initiation.


Clinical Trial Description

This study is a randomized controlled clinical trial with an open-label and parallel-group design conducted in the clinical oncology department of Beni-Suef University Hospital. A total of 50 patients with head and neck cancer receiving RT were randomly assigned into either study group: Group 1 (Intervention group): This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks Group 2 (Control group): This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks. These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets) 1. Oral mucositis severity was measured by the World Health Organization Toxicity Scale (WHO grading system). Based on the symptomatic (oral pain), and functional clinical features of every patient (ability to drink and eat) as well as the presence of lesions (ulcers, erythema), the measurements were categorized to Grade I: presence of soreness and erythema, Grade II: presence of painful erythema and ulcerations that do not affect the patient solid food intake, Grade Ш: confluent ulceration that affect the solid food intake and require liquid diet, and Grade ΙV: the patient requires parenteral nutrition. 2. Discomfort and pain severity were recorded using the Numeric Rating Scale (NRS), which is categorized to no pain (NRS 0), mild pain (NRS 1-3), moderate pain (NRS 4-7), and unbearable pain (NRS 8-10). Patients were asked to assign a numerical score on the scale verbally to rate their pain intensity, and the number was recorded 3. Dry mouth, Dysphagia was measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06117904
Study type Interventional
Source Beni-Suef University
Contact
Status Active, not recruiting
Phase N/A
Start date January 1, 2023
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT02252926 - Local Anesthetic Treatment of Oral Pain in Patients With Mucositis Phase 2
Completed NCT01155609 - L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer N/A
Completed NCT00357942 - Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy Phase 4
Completed NCT00360685 - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX N/A
Completed NCT04586491 - The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients N/A
Withdrawn NCT02589860 - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Not yet recruiting NCT02506231 - The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Phase 2/Phase 3
Completed NCT02639377 - Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis Phase 2
Completed NCT02605382 - Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis Phase 2
Terminated NCT02575313 - The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer Phase 1/Phase 2
Completed NCT00956254 - Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis Phase 3
Completed NCT00584597 - A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis Phase 1
Enrolling by invitation NCT05590117 - Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer Early Phase 1
Completed NCT05635929 - Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients. N/A
Completed NCT05181943 - Effectiveness of Photo-biomodulation in the Treatment of Chemotherapy Induced Mucositis N/A
Completed NCT03713567 - Clinical, Immunological and Microbiological Evaluation of Experimental Gingivitis and Peri-implant Mucositis N/A
Completed NCT02671812 - Outcome After Dental Implant Treatment
Terminated NCT02273752 - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Phase 2
Recruiting NCT01707641 - Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer Phase 4
Completed NCT01015183 - Prevention Chemotherapy Induced Mucositis by Zinc Sulfate Phase 2/Phase 3